Eli Lilly has been a leader in the diabetes drug market for decades. That business is still performing well, and over the past five years, the pharmaceutical giant has also made significant clinical and regulatory progress in the related anti-obesity space. It earned approval for Mounjaro and Zepbound, which treat obesity and diabetes (respectively) and are already generating well over $1 billion per quarter. Eli Lilly (LLY 1.12%) has been on fire over the past two years. The drugmaker has generated excelle ...

The market is worried about Novo Nordisk's grip on the weight loss market, evidenced by the stock plummeting over 52% from its mid-2024 high. Does Wall Street have it wrong, or is Novo Nordisk fumbling a generational growth opportunity? Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels. Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry's hottest ...

If you can't beat Novo Nordisk, maybe you should join 'em?Novo Nordisk (NVO 1.96%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.As Reuters reports today, an online weight loss company called Noom has begun selling smaller doses of compounded versions of Novo Nordisk's Wegovy GLP-1 drug. This development comes as the compounding pharmacy industry seeks a way to coexist with the big pharmaceutical companies that invented -- and patented -- GLP-1 ...